{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:53:59Z","timestamp":1789592039809,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.euroneuro.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T21:16:29Z","timestamp":1491945389000},"page":"470-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia"],"prefix":"10.1016","volume":"27","author":[{"given":"Reef","family":"Einoch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mandiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa B.H.","family":"Youdim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Bilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.lfs.2006.01.039","article-title":"Haloperidol and atypical antipsychotics share a same action of decreasing P75(NTR) mRNA levels in PC12 cells","volume":"79","author":"Bai","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jnr.10440","article-title":"Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs","volume":"71","author":"Bai","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib3","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib4","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1517\/14656560903130609","article-title":"Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data","volume":"10","author":"Bobo","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2006.12.026","article-title":"Brain derived neurotropic factor in first-episode psychosis","volume":"91","author":"Buckley","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0006-3223(01)01083-6","article-title":"Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication","volume":"50","author":"Chen","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-009-1665-6","article-title":"Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes","volume":"207","author":"Chen","year":"2009","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S1461145705005626","article-title":"The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex","volume":"9","author":"Chertkow","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib9","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-009-0255-4","article-title":"Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia","volume":"116","author":"Chertkow","year":"2009","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-8993(02)03215-8","article-title":"Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration","volume":"954","author":"Chlan-Fourney","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0028-3908(03)00077-7","article-title":"Bi-phasic change in BDNF gene expression following antidepressant drug treatment","volume":"44","author":"Coppell","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S1461145710000106","article-title":"The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment","volume":"14","author":"Danovich","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00213-011-2530-y","article-title":"Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex","volume":"220","author":"Danovich","year":"2012","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0028-3908(03)00198-9","article-title":"Differential regulation of brain derived neurotrophic factor transcripts by antidepressant treatments in the adult rat brain","volume":"45","author":"Dias","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0006-3223(00)00935-5","article-title":"Neuronal plasticity and survival in mood disorders","volume":"48","author":"Duman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2008.01.017","article-title":"Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia","volume":"101","author":"Ikeda","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2009.12.035","article-title":"Decreased BDNF in patients with antipsychotic naive first episode schizophrenia","volume":"119","author":"Jindal","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-3956(02)00061-4","article-title":"Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability","volume":"37","author":"Koch","year":"2003","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1358\/dnp.2007.20.7.1149632","article-title":"The role of glycogen synthase kinase-3beta in schizophrenia","volume":"20","author":"Koros","year":"2007","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00702-004-0166-3","article-title":"Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients","volume":"111","author":"Kozlovsky","year":"2004","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.nbd.2005.03.023","article-title":"Antidepressants and prolonged stress in rats modulate CAM-L1, laminin, and pCREB, implicated in neuronal plasticity","volume":"20","author":"Laifenfeld","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrn1648","article-title":"Cortical inhibitory neurons and schizophrenia","volume":"6","author":"Lewis","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1461145706006547","article-title":"Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics","volume":"10","author":"Li","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s702-002-8239-6","article-title":"Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P?","volume":"109","author":"Manier","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1523\/JNEUROSCI.16-07-02365.1996","article-title":"Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus","volume":"16","author":"Nibuya","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0006-3223(94)00216-P","article-title":"Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement","volume":"38","author":"Nibuya","year":"1995","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib29","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.pnpbp.2011.09.004","article-title":"Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia","volume":"35","author":"Niitsu","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib30","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2006"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1476-5381.2011.01516.x","article-title":"Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects","volume":"165","author":"Pilar-Cuellar","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib32","doi-asserted-by":"crossref","first-page":"21667","DOI":"10.1074\/jbc.M110.201582","article-title":"Positive feedback regulation between gamma-aminobutyric acid type A (GABA(A)) receptor signaling and brain-derived neurotrophic factor (BDNF) release in developing neurons","volume":"286","author":"Porcher","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jpsychires.2012.04.016","article-title":"The administration of olanzapine and fluoxetine has synergistic effects on intracellular survival pathways in the rat brain","volume":"46","author":"Reus","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/15622970802182733","article-title":"Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics","volume":"11","author":"Rizos","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005581.pub2","article-title":"Antidepressants for the negative symptoms of schizophrenia","author":"Rummel","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/tcrm.2006.2.2.187","article-title":"The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination","volume":"2","author":"Shelton","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euroneuro.2004.12.005","article-title":"The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia","volume":"15","author":"Shoval","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00004850-200311000-00001","article-title":"Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia","volume":"18","author":"Silver","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib39","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/0006-3223(92)90279-9","article-title":"Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study","volume":"31","author":"Silver","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib40","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JCP.0b013e3182983d42","article-title":"Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center","volume":"33","author":"Silver","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/oxfordjournals.schbul.a007026","article-title":"Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms","volume":"29","author":"Silver","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib42","first-page":"363","article-title":"The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions","volume":"20","author":"Silver","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1017\/S1461145710001471","article-title":"SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients","volume":"14","author":"Silver","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/YIC.0000000000000070","article-title":"Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients","volume":"30","author":"Silver","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"Suppl 9","key":"10.1016\/j.euroneuro.2017.03.005_bib45","first-page":"9","article-title":"The neurobiology of cognition in schizophrenia","volume":"67","author":"Tamminga","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 3","key":"10.1016\/j.euroneuro.2017.03.005_bib46","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004850-199803003-00004","article-title":"The role of negative symptoms and cognitive dysfunction in schizophrenia outcome","volume":"13","author":"Tamminga","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib47","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0896-6273(03)00356-8","article-title":"Control of synaptic strength, a novel function of Akt","volume":"38","author":"Wang","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib48","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.mp.4001678","article-title":"Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia","volume":"10","author":"Weickert","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mcn.2010.08.007","article-title":"Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia","volume":"46","author":"Wong","year":"2011","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.euroneuro.2017.03.005_bib50","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.pnpbp.2009.08.011","article-title":"Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics","volume":"33","author":"Xiu","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.03.005_bib51","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.neuropharm.2011.12.014","article-title":"Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia","volume":"62","author":"Zhang","year":"2012","journal-title":"Neuropharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17301876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T19:18:46Z","timestamp":1569007126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17301876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924977X17301876"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.03.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}